free web stats

Respiratory syncytial virus (“RSV”)

VBI Vaccines Awarded NRC-IRAP Funding to Leverage its eVLP Platform in the Development of a Novel RSV Vaccine Candidate

By | Press Releases, Respiratory syncytial virus (“RSV”) | No Comments
VBI Vaccines Inc. (Nasdaq: VBIV) (“VBI”) has been awarded up to $350,000 CAD in grant funding by the National Research Council-Industrial Research Assistance Program (“NRC-IRAP”) to apply VBI’s eVLP Platform in the development of a respiratory syncytial virus (“RSV”) vaccine...
Read More